The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2020 | AutoHCT in DLBCL in the CAR-T era
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a study which reviewed if using autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) was appropriate in patients only acheiving a PET/CT positive partial remission prior to HCT in the CAR-T cell era. The study reviewed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
